

Neuroendocrine neoplasms and somatostatin receptor subtypes expression

Jerzy Hankus, Romana Tomaszewska

Chair and Department of Pathomorphology, Jagiellonian University Medical College

[Received 30 VI 2016; Accepted 13 VII 2016]

Abstract

Neuroendocrine neoplasms (NENs) show wide spectrum of clinical course — from benign biological potential to recurrences and rapidly progressive disease. Somatostatin analogs that bind to somatostatin receptor are part of the therapy; detection and evaluation of activation of somatostatin receptor subtypes are part of the process of new therapy induction. When using RT-PCR method and immunohistochemistry, it is possible to detect more than two SSTR subtypes in majority or all neuroendocrine neoplasms regardless tumor origin. Generally with some exceptions, from the viewpoint of tumor grade — apart the site of origin, there is a tendency to decrease the percentage of SSTRs expression; 100% (G1, 2)–85.7% (G3) for SSTR 1; 81.8% (G1, 2)–61.9% (G3) for SSTR 2; 54.5% (G1, 2)–52.4% (G3) for SSTR 3; 9% (G1, 2)–4.8% (G3) for SSTR 5. Different studies indicate significant differences in the expression of SSTR 1 and 2A and 2B between NEC G3 small cell type and non-small cell type. Further research on SSTRs expression in NEN could serve as base to development and improvement of somatostatin analogs' pharmacotherapy in patients with unsatisfactory course.

KEY words: somatostatin, somatostatin receptor, SSTR, neuroendocrine neoplasm, NEN, expression

Nucl Med Rev 2016; 19, 2: 111–117

Introduction

Somatostatin analogs take a role in pharmacotherapy from the early 1980s [1]. Somatostatin binds to all somatostatin receptor subtypes (SSTR 1–5), in contrast to octreotide (first synthesized somatostatin analog) and lanreotide, which bind only with a high affinity to SSTR 2 and SSTR 5 [2, 3]. Expression of somatostatin receptors by endocrine tumors is essential for the use of the somatostatin analogs in pharmacotherapy. In 1973, somatostatin was isolated from sheep hypothalamus in the search for the hormone responsible for stimulating the release of GH from the anterior pituitary [4].

Many physiological functions in the GI tract (e.g. motility, gastric acid production, pancreatic enzyme secretion, bile secretion) are inhibited by somatostatin. It also acts as a secretory pan-inhibitor, by suppressing secretion from the anterior pituitary gland (e.g. GH, prolactin, TRH, ACTH) [5–7], gastrointestinal tract (e.g. cholecystokinin, gastrin, secretin, vasoactive intestinal peptide), endocrine pancreas (e.g. glucagon, insulin, and pancreatic polypeptide) [8], thyroid (e.g. triiodothyronine, thyroxine, and calcitonin), kidney and adrenals (e.g. renin aldosterone system) [9]. Control of the cell proliferation in normal tissues and tumors was as well recorded [10–13].

Two biologically active forms of somatostatin: somatostatin-14 and somatostatin-28 act through high affinity G protein-coupled membrane receptors. Proteolytic processing of larger precursor molecules (prepro-somatostatin and pro-somatostatin) forms the somatostatin [14, 15]. Five somatostatin receptor (SSTR) subtype genes have been cloned and described — SSTR 1, SSTR 2, SSTR 3, SSTR 4 and SSTR 5 [16]. The genes which encode the five SSTR subtypes are localized on different chromosomes [17]. Alternative splicing can generate two forms of the SSTR2 receptor (SSTR 2A and SSTR 2B) [18, 19].

Somatostatin influence on cells has a wide spectrum, through binding to its SSTR subtype(s), and activation of the second messenger system. These systems include (1) inhibition of adenylate cyclase activity and (2) activity of calcium channels, as well as (3) stimulation of phosphotyrosine phosphatase or (4) MAPK (mitogen-activated protein) kinase activity [17, 20, 21]. The inhibitory effects of somatostatin on adenylate cyclase activity and on the influx of calcium are linked to inhibition of secretion processes.

Activation of SSTR 1, 2, 4 and 5 promotes cell cycle arrest (via modulation of MAPK pathway) [22, 23]. Interestingly, SSTR 2 and SSTR 3 trigger apoptosis (accompanied by p53 and Bax protein activation) [24–26].

A high density of SSTRs are expressed in tumors, arising from tissues which are target for the somatostatin [27–31].

Many tumors express the SSTR: e.g. pituitary adenomas, pancreatic endocrine tumors, carcinoids, paragangliomas, pheochromocytomas, small cell lung cancers, medullary thyroid carcinomas, breast cancers and malignant lymphomas [28, 32].

Correspondence to: Jerzy Hankus, MD
Jagiellonian University Medical College
ul. Grzegorzewska 16, 31-531 Kraków
Tel: 48 500 877 578; Fax: 12 411 97 25
e-mail: jerzy.hankus@uj.edu.pl

Multiple SSTR subtypes are coexpressed by the majority of the SSTR-positive tumors and essential variation in their expression between the different tumor types and among tumors of the same type were described [33–36].

SSTR 2 predominance is generally found in more than 80% of the endocrine pancreatic and endocrine GI tract tumors [29, 31, 37–39].

Different methods have been used for identification SSTR subtypes expression in tissue samples. The most relevant are: the specific mRNA of SSTR detection (e.g. in situ hybridization, RNase protection assays and RT-PCR), using radiolabeled somatostatin analogs and immunohistochemistry. IHC based on SSTR-specific antibodies seems to be widely available and cost effective method which identifies SSTR subtypes — it is worthy to mention that many researchers noticed that this method needs the precise standardization [40–48].

Many articles bring information about SSTR expression using the nuclear medicine methods — for this knowledge we send the reader to the references [49–54].

Pituitary adenoma

Pituitary adenomas (PA) in the majority have a benign biological potential. These tumors are classified based on the hormones that are produced by the neoplastic cells (GH, prolactin, adrenocorticotropin, thyrotropin, follitropin, or luteinizing hormone) — some of them can secrete two hormones (GH and prolactin as the most common combination), and rarely, pituitary adenomas are pluri-hormonal. Clinically non-functioning adenomas (CNFA) lack the typical hypersecretion of the functional pituitary adenomas and do not produce clinical symptoms of hormone excess.

Recent data based on mRNA and immunohistochemistry analysis showed that in (GH) adenomas SSTR 2, SSTR 5, SSTR 3 and SSTR 1 transcripts were expressed in descending level order. Macroprolactinomas revealed significant amount of SSTR 1 transcripts. Corticotroph adenomas showed expression of SSTR 2 and SSTR 1 transcripts, but levels of SSTR 5 transcripts were very low. Patients with CNFA dominantly expressed SSTR 3 and SSTR 2mRNA [55], other data demonstrate expression of SSTR 1-5 by all CNFA, but with very low/or missing levels of SSTR 4 and 5 [56–58]. High relative expression (ratio to β -glucuronidase mRNA > 1) of SSTR 1 was found in 7.5 %, SSTR 2 in 7 %, SSTR 3 in 4 % and SSTR 5 in 0.5 % of tumors. Among histological adenoma types in null cell adenomas high levels of SSTR 1 and SSTR 2 were observed, accompanied with low levels of SSTR 3. In gonadotrophs adenomas, expression of SSTR 3, SSTR 2 and SSTR 1 in descending order was demonstrated. Silent ACTH adenomas showed expression of SSTR 2, SSTR 1, SSTR 5 and low level of SSTR 3 [56]. In recent years, scientist investigate coexpression of the SSTRs and other receptors in many neuroendocrine neoplasms (e.g. dopamine 2) [55, 56].

Gastro-intestinal tract and Pancreas

Neuroendocrine neoplasms (NEN) in the digestive system and pancreas are divided into neuroendocrine tumors (NET; low to intermediate grade, G1 and G2 respectively) and neuroendocrine carcinomas (NEC; poorly differentiated — high grade, G3). Among

NECs, large cell NEC and small cell NEC can be recognized. Mixed adenoneuroendocrine carcinomas (MANEC) are neoplasms with both high grade neuroendocrine and adenocarcinoma features. Classification criteria of NENs are common to all GI and pancreatic neuroendocrine neoplasms. NENs can be functional or non-functional [59].

Grossly NETs have tendency to be small, circumscribed, and in GI tract they can be covered by a flattened mucosa [60] or have the gross appearance of gastric polyps [61]. Microscopically, the predominant pattern of growth may be microglandular, trabecular or insular. The nuclei are regular and normochromatic, mitoses are scanty, necrosis is usually absent, and vascularization is florid. Focal mucin positivity may be present. Immunohistochemically, GI NENs are positive for neuron-specific enolase, chromogranin, synaptophysin, and keratin. NECs may form a large, sometimes fungating mass deeply infiltrating the GI wall and often metastatic to lymph nodes and liver. They are composed of large, poorly formed trabeculae, nests or sheets of anaplastic round, polyhedral to spindle cells, small to fairly large in size, and immunoreactive for general neuroendocrine markers including chromogranin A, synaptophysin, neural cell adhesion molecule (NCAM1/CD56) or neuron-specific enolase [59].

Immunohistochemistry revealed that SSTR 1, SSTR 2A, 3 and 5 are expressed in gastrinomas, insulinomas and carcinoid tumors. Immunostaining of the specific antibodies is non-homogenous and shows differences between SSTR subtypes and between commercial antibodies. Generally immunoreactivity for SSTR 2 is localized in the plasma membrane in contrast to SSTR 1, 3 and 5 which stain mainly the cytoplasm.

SSTR 1 was expressed in 30% of gastrinomas, 31% of insulinomas and 37% of NETs. SSTR 2a showed expression in 100% of gastrinomas, 58% of insulinomas and 86% of NETs. Immunostaining for SSTR 3 was observed in 79% of gastrinomas, 78% of insulinomas and 71% of NETs. SSTR 5 immunoreactivity was detected in 76% gastrinomas, 78% of insulinomas and 83% of NETs [62]. Other researchers also indicate SSTR 2 as the commonest SSTR expressed, which is accompanied by co-expression of SSTR 3 and 5 in 32% and 24% of cases, respectively [63].

From the viewpoint of tumor localization: 85.5% of pancreatic, 100% of gastric, 70% of intestinal, 85.7% of appendiceal and 100% of rectal NENs show SSTR 2. SSTR 5 expression is present in: 61.9% of pancreatic, 37.5% of gastric, 70% of intestinal, 71.5% of appendiceal and 66.6% of rectal NENs. According to the tumor grade, SSTR 2 is expressed in 91% of grade 1, 82.8% of grade 2 and 100% of grade 3 GI NENs. SSTR 5 show expression in 81.8%, 60% and 0% of grade 1, 2 and 3, respectively [64].

Lung

The pulmonary neuroendocrine tumors include typical carcinoid (TC), atypical carcinoid (AC), small cell carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC). These tumors are characterized by similar microscopic appearance, like other neuroendocrine tumors in the body — they have organoid nesting, palisading and trabecular pattern with mitotic activity and presence of necrosis as the distinguishing features (TC: < 2 mitoses per 2 mm² and no evidence of necrosis. AC: 2–10 mitoses per 2 mm² and/or focal necrosis).




Figure 1. Medullary thyroid carcinoma — SSTR 1. Medullary thyroid carcinoma (upper left) show weak SSTR 1 expression




Figure 2. Medullary thyroid carcinoma — SSTR 2a. Medullary thyroid carcinoma (upper left) show SSTR 2a expression

LCNEC is differentiated from SCLC by larger cell size, abundant cytoplasm and prominent nucleoli. Mitotic activity is high (10–11 mitoses/10 hpf). Prominent nuclear molding and deposition of hematoxylin-stained material (DNA) in blood vessel walls are characteristic for SCLC. These tumors are positive for chromogranin, synaptophysin and NCAM (CD56), about 50% of LCNECs also express TTF-1.

TC and AC occur in significantly younger patients than SCLC and LCNEC. They present as firm and well-demarcated tumors, with predilection to bronchi (frequently endobronchial growth). TC is evenly distributed in the lung parenchyma, while AC arises more commonly in small peripheral bronchi. Clinical symptoms are related to bronchial obstruction (cough and hemoptysis as the most common), Cushing's syndrome and carcinoid syndrome are rare.

SCLC has tendency to occur in central location with locoregional spread, commonly accompanied by paraneoplastic syndromes. On macroscopy it presents as a white-tan, soft and friable mass with extensive necrosis and frequent nodal involvement.

LCNEC occurs preferentially as peripheral mass, but may also involve subsegmental or large bronchi. It spreads on visceral pleura and chest wall. Typically LCNECs do not produce clinical symptoms of hormone excess [65–70].

Typical carcinoids (TC) show immunoexpression of SSTR 1, 2A, 2B, 3, 4, and 5 in 79%, 96%, 66%, 49%, 5%, and 0%, respectively. Atypical carcinoids (AC) expression of SSTR 1, 2A, 2B, 3, 4, and 5 was observed in 77%, 77%, 77%, 33%, 0% and 0%, respectively. In Large cell NECs (LCNEC), immunoexpression of SSTR 1, 2A, 2B, 3, 4, and 5 was observed in 60%, 60%, 30%, 40%, 0%, and 15% of cases, respectively. Small-cell carcinomas (SCLC) show immunoexpression of SSTR 1, 2A, 2B, 3, 4, and 5 in 27%, 69%, 24%, 15%, 0%, and 0% of cases, respectively.

Tsuta et al. demonstrated that SSTR 1, 2A, 2B, 3 and 4 have a tendency toward decreased expression in well to poorly differentiated NECs [71].

Other study of TC and AC [58] also indicates SSTR 2A as a most frequently expressed (72% of cases), followed by SSTR 1 (63%),

SSTR 5 (40%) and SSTR 3 (20%), whereas researchers did not record SSTR 4 expression.

83% of TCs and ACs are positive for at least one SSTR subtype, these which are negative for SSTR 2A, show expression of another SSTR in nearly half cases (48%) — among them 35% are positive for SSTR 1, 11% for SSTR 3 and 11% for SSTR 5.

There is no difference in distribution of SSTR 1–5 compared with TNM parameters [72].

Paraganglioma/pheochromocytoma

Pheochromocytoma (PCC) and paraganglioma (PGL) are neuroendocrine tumors derived from adrenal chromaffin cells and extra-adrenal paraganglia, respectively. Hereditary tumors are frequently diagnosed before 40 years of age, while sporadic tumors are usually discovered in patients aged 40 to 50 years. Clinical presentation results from effects of secreted catecholamines, including: hypertension, tachycardia, pallor, headache, and anxiety; but up to 25% of pheochromocytomas are asymptomatic. Macroscopically tumors are variable in size and weight (up to > 2000 g), with round to oval and sharply circumscribed presentation. Cut surface shows a dusky red-brown mass with possible marked hemorrhage and necrosis. Tumor cells vary in size and shape and show round nuclei, prominent nucleoli and granular amphiphilic to basophilic cytoplasm. They are arranged in well-defined nests (Zellballen), surrounded by the sustentacular cells. Cell nests can be separated by thin strands of fibrovascular stroma.

Patients with MEN II syndrome may demonstrate tumors accompanied by adrenal medullary hyperplasia, occasionally multiple or bilateral [73–76].

Among SSTRs, type 2 and 1 are the most commonly expressed subtypes in PCCs and PGLs. Expression of SSTR 3 and SSTR 5 is more frequent in PCCs than PGLs. More precise data show SSTR expression level in PCCs: 95%, 100%, 56% and 54% for SSTR 1, 2, 3 and 5, respectively. SSTR 1, 2, 3 and 5 are expressed in PGLs in: 92%, 100%, 31% and 31%, respectively. Researchers did




Figure 3. Medullary thyroid carcinoma — SSTR 5. Medullary thyroid carcinoma (upper left) and adjacent parenchyma show SSTR 5 expression

not indicate significant differences in SSTRs expression between sporadic and hereditary tumor types [77].

Merkel cell carcinoma

Merkel cell carcinoma is an uncommon neoplasm of the skin with neuroendocrine differentiation, which involves commonly head and extremities. It is usually small (from 0.8 cm to 4 cm), pink, solitary nodule, rarely with multiple nodules presentation. Tumor is composed of small, round, blue cells with scant cytoplasm and irregular nuclei with uniformly distributed chromatin. Nucleoli are inconspicuous, frequent mitotic figures and individually necrotic tumor cells are commonly visible. Tumor cells are positive for chromogranin, synaptophysin, neuron-specific enolase and cytokeratin 20 [78–83].

Overall, 76.5% of Merkel cell carcinomas express at least one of SSTRs. SSTR 2A and SSTR 5 are expressed in 59.2% and in 44.9% of tumors, respectively. Expression of SSTRs is not associated with clinical characteristics, Ki67 proliferative index and survival [84].

Neuroblastoma

Neuroblastoma is the most common solid tumor of young children (90% occur < 5 years); it shows minimal to none maturation and is composed of small round blue cells arranged in nodular aggregates separated by fibrovascular septa. Homer-Wright pseudorosettes can be visible. Macroscopically tumor forms large mass with a gray cut surface, often accompanied by hemorrhage and necrosis. Neuroblastoma cells are positive for neurofilament, synaptophysin, chromogranin and neuron-specific enolase [85–90].

Neuroblastomas show expression in 66.7%, 81.5%, 9.3%, 37% and 0% for SSTR 1, 2, 3, 4 and 5 respectively. The favorable histology group of NBs are characterized by higher SSTRs expression than the unfavorable histology group — the researchers indicate significant differences in SSTR 1, 2 and 4 expression. SSTR subtypes expression in normal tissues from the adrenal medulla and sympathetic ganglia are similar to those of ganglioneuromas and

ganglioneuroblastomas, with rates being 100% for SSTR 1, approximately 90% for SSTR 2, approximately 40% for SSTR 3, 100% for SSTR 4 and 0% for SSTR 5 [91].

Medullary thyroid carcinoma

Medullary thyroid carcinoma is a malignant entity derived from C cells and accounts for up to 5% of thyroid malignancies. Tumor can be sporadic (80%) or hereditary (20%, related to familial medullary thyroid carcinoma, MEN IIA and MEN IIB). Elevated level of calcitonin in serum is a useful parameter to monitor residua, recurrent or metastatic disease. Macroscopically tumor occurs often as circumscribed, tan-yellow mass with firm consistency. Most common localization is upper and middle third of lobe (which corresponds to predominant C cells localization); in hereditary types multifocal nodules may occur. Medullary thyroid carcinoma presents variety of histologic patterns: solid, sheet-like, lobular, trabecular and insular. Tumor cells are round, polygonal, fusiform and commonly mixed cell types are visible, with salt-pepper chromatin pattern appearance. Stromal deposition of amyloid occurs in about 80% of cases. Immunohistochemistry reveals positive reaction to calcitonin, chromogranin, synaptophysin, carcinoembryonic antigen and TTF 1. Congo red stains amyloid material and shows birefringence in polarized light [92–95].

Researchers demonstrated SSTRs by IHC in medullary thyroid carcinoma in 1970s and 1980s, later works showed that 85% of tumors express at least one SSTR; 49%, 43%, 47%, 4% and 57% tumors are positive for SSTR 1, 2, 3, 4 and 5, respectively. There is no correlation between SSTR expression and clinical data, TNM and histological type [96].

Others studies analyzed SSTR expression in other thyroid malignancies — they also showed that SSTR 5 is commonly expressed in thyroid neoplastic and non-neoplastic entities (86.2–100%) [97–98].

Summary

Using RT-PCR method and immunohistochemistry it is possible to detect more than two SSTR subtypes in majority or all neuroendocrine neoplasms regardless tumor origin. Generally with some exceptions, from the viewpoint of tumor grade — apart the site of origin, there is a tendency to decrease the percentage of SSTRs expression; 100% (G1, 2)–85.7% (G3) for SSTR 1; 81.8% (G1, 2)–61.9% (G3) for SSTR 2; 54.5% (G1, 2)–52.4% (G3) for SSTR 3; 9% (G1, 2)–4.8% (G3) for SSTR 5. Different studies indicate significant difference in the expression of SSTR 1 and 2A and 2B between NEC G3 small cell type and non-small cell type [71, 99].

Further research on SSTRs expression in NEN could serve as a base for development and improvement of somatostatin analogs' pharmacotherapy in patients with unsatisfactory course.

References

1. Hubalewska-Dydejczyk A, Signore A, de Jong M, Dierckx RA, Buscombe JR, Van de Wiele C. Somatostatin Analogues From Research to Clinical Practice. John Wiley & Sons, New Jersey 2015.
2. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. *N Engl J Med* 1996; 334: 246–254.
3. Patel YC. Somatostatin and its receptor family. *Front Neuroendocrinol* 1999; 20: 157–198.

4. Brazeau P, Vale W, Burgus R et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. *Science* 1973; 179: 77–79.
5. Siler TM, Yen SC, Vale W, Guillemin R. Inhibition by somatostatin on the release of TSH induced in man by thyrotropin-releasing factor. *J Clin Endocrinol Metab* 1974; 38: 742–745.
6. Drouin J, De Léan A, Rainville D, Lachance R, Labrie F. Characteristics of the interaction between thyrotropin-releasing hormone and somatostatin for thyrotropin and prolactin release. *Endocrinology* 1976; 98: 514–521.
7. Tyrrell JB, Lorenzi M, Gerich JE, Forsham PH. Inhibition by somatostatin of ACTH secretion in Nelson's syndrome. *J Clin Endocrinol Metab* 1975; 40: 1125–1127.
8. Koerker DJ, Ruch W, Chideckel E et al. Somatostatin: hypothalamic inhibitor of the endocrine pancreas. *Science* 1974; 184: 482–484.
9. Gomez-Pan A, Snow MH, Piercy DA et al. Actions of growth hormone-release inhibiting hormone (somatostatin) on the renin aldosterone system. *J Clin Endocrinol Metab* 1976; 43: 240–243.
10. Reichlin S. Somatostatin. *N Engl J Med* 1983; 309: 1495–1501.
11. Reichlin S. Somatostatin (second of two parts). *N Engl J Med* 1983; 309: 1556–1563.
12. Schally AV. Oncological applications of somatostatin analogues. *Cancer Res* 1988; 48: 6977–6985.
13. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. *Endocr Rev* 1991; 12: 450–482.
14. Krulich L, Dhariwal AP, McCann SM. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. *Endocrinology* 1968; 83: 783–790.
15. Brazeau P, Vale W, Burgus R et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. *Science* 1973; 179: 77–79.
16. Hoyer D, Lübbert H, Bruns C. Molecular pharmacology of somatostatin receptors. *Naunyn Schmiedebergs Arch Pharmacol* 1994; 350: 441–453.
17. Patel YC. Molecular pharmacology of somatostatin receptor subtypes. *J Endocrinol Invest* 1997; 20: 348–367.
18. Vanetti M, Kouba M, Wang X, Vogt G, Höllt V. Cloning and expression of a novel mouse somatostatin receptor (SSTR2B). *FEBS Lett* 1992; 311: 290–294.
19. Patel YC, Greenwood M, Kent G, Panetta R, Srikant CB. Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. *Biochem Biophys Res Commun* 1993; 192: 288–294.
20. Reisine T, Bell GI. Molecular biology of somatostatin receptors. *Endocr Rev* 1995; 16: 427–442.
21. Patel YC. Somatostatin and its receptor family. *Front Neuroendocrinol* 1999; 20: 157–198.
22. Cheung NW, Boyages SC. Somatostatin-14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumor cell proliferation via a transient G0/G1 cell cycle block. *Endocrinology* 1995; 136: 4174–4181.
23. Srikant CB. Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201-995 in AtT-20 mouse pituitary cells. *Biochem Biophys Res Commun* 1995; 209: 400–406.
24. Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. *Mol Endocrinol* 1996; 10: 1688–1696.
25. Teijeiro R, Rios R, Costoya JA et al. Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53. *Cell Physiol Biochem* 2002; 12: 31–38.
26. Ferrante E, Pellegrini C, Bondioni S et al. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. *Endocr Relat Cancer* 2006; 13: 955–962.
27. Reubi JC, Krenning E, Lamberts SW, Kvols L. In vitro detection of somatostatin receptors in human tumors. *Metabolism* 1992; 41 (9 Suppl 2): 104–110.
28. Reubi JC, Laissue J, Krenning E, Lamberts SW. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. *J Steroid Biochem Mol Biol* 1992; 43: 27–35.
29. Reubi JC, Laissue J, Waser B, Horisberger U, Schaer JC. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. *Ann N Y Acad Sci* 1994; 733: 122–137.
30. Reubi JC, Schaer JC, Laissue JA, Waser B. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. *Metabolism* 1996; 45 (Suppl 1): 39–41.
31. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. *Eur J Nucl Med* 2001; 28: 836–846.
32. Vikić-Topić S, Raisch KP, Kvols LK, Vuk-Pavlović S. Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. *J Clin Endocrinol Metab* 1995; 80: 2974–2979.
33. Reubi JC, Kappeler A, Waser B, Laissue J, Hipkin RW, Schonbrunn A. Immunohistochemical localization of somatostatin receptors sst2A in human tumors. *Am J Pathol* 1998; 153: 233–245.
34. Schulz S, Schmitt J, Wiborny D et al. Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. *Clin Cancer Res* 1998; 4: 2047–2052.
35. Kimura N, Pilichowska M, Date F, Kimura I, Schindler M. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. *Clin Cancer Res* 1999; 5: 3483–3487.
36. Hofland LJ, Liu Q, Van Koetsveld PM et al. Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. *J Clin Endocrinol Metab* 1999; 84: 775–780.
37. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW. Peptide receptors in gut endocrine tumours. *Baillieres Clin Gastroenterol* 1996; 10: 571–587.
38. Papotti M, Bongiovanni M, Volante M et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. *Virchows Arch* 2002; 440: 461–475. *Epub* 2002 Mar 23.
39. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. *Eur J Nucl Med Mol Imaging* 2003; 30: 781–793.
40. Kubota A, Yamada Y, Kagimoto S et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. *J Clin Invest* 1994; 93: 1321–1325.
41. Panetta R, Patel YC. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. *Life Sci* 1995; 56: 333–342.
42. Lamberts SW, Hofland LJ, van Koetsveld PM et al. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. *J Clin Endocrinol Metab* 1990; 71: 566–574.
43. Reubi JC, Maurer R, von Werder K, Torhorst J, Klijn JG, Lamberts SW. Somatostatin receptors in human endocrine tumors. *Cancer Res* 1987; 47: 551–558.
44. Kong H, DePaoli AM, Breder CD, Yasuda K, Bell GI, Reisine T. Differential expression of messenger RNAs for somatostatin receptor subtypes SSTR1, SSTR2 and SSTR3 in adult rat brain: analysis by RNA blotting and in situ hybridization histochemistry. *Neuroscience* 1994; 59: 175–184.
45. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. *Cancer Res* 1994; 54: 3455–3459.
46. Janson ET, Gobl A, Kälkner KM, Oberg K. A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization

- for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. *Cancer Res* 1996; 56: 2561–2565.
47. Hofland LJ, Liu Q, Van Koetsveld PM et al. Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. *J Clin Endocrinol Metab* 1999; 84: 775–780.
 48. Reubi JC, Kappeler A, Waser B, Laissue J, Hipkin RW, Schonbrunn A. Immunohistochemical localization of somatostatin receptors sst2A in human tumors. *Am J Pathol* 1998; 153: 233–245.
 49. Öberg K, Sundin A. Imaging of Neuroendocrine Tumors. *Front Horm Res* 2016; 45: 142–151.
 50. Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. *Radiographics* 2015; 35: 500–516.
 51. Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. *Front Neuroendocrinol* 2013; 34: 228–252.
 52. Pepe G, Moncayo R, Bombardieri E, Chiti A. Somatostatin receptor SPECT. *Eur J Nucl Med Mol Imaging* 2012; 39 (Suppl 1): S41–51.
 53. Kunikowska J, Ziemnicka K, Pawlak D et al. Medullary thyroid carcinoma — PET/CT imaging with 68Ga-labelled gastrin and somatostatin analogues. *Endokrynol Pol* 2016; 67: 68–71.
 54. Buder K, Lapa C, Kreissl MC et al. Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging. *BMC Cancer* 2014; 14: 268.
 55. Drastikova M, Beranek M, Gabalec F et al. Expression profiles of somatostatin, dopamine, and estrogen receptors in pituitary adenomas determined by means of synthetic multilocus calibrators. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 2016; 160: 238–243.
 56. Gabalec F, Drastikova M, Cesak T et al. Dopamine 2 and somatostatin 1-5 receptors coexpression in clinically non-functioning pituitary adenomas. *Physiol Res* 2015; 64: 369–377.
 57. Taboada GF, Luque RM, Bastos W et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. *Eur J Endocrinol* 2007; 156: 65–74.
 58. Neto LV, Machado Ede O, Luque RM et al. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. *J Clin Endocrinol Metab* 2009; 94: 1931–1937.
 59. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO 2010 Tumors of digestive system 2010.
 60. Lattes R, Grossi C. Carcinoid tumors of the stomach. *Cancer* 1956; 9: 698–711.
 61. DeSchryver-Kecsckemeti K, Clouse RE, Kraus FT. Surgical pathology of gastric and duodenal neuroendocrine tumors masquerading clinically as common polyps. *Semin Diagn Pathol* 1984; 1: 5–12.
 62. Kulaksiz H, Eissele R, Rössler D et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. *Gut* 2002; 50: 52–60.
 63. Diakou E, Alexandraki KI, Tsolakis AV et al. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores. *Clin Endocrinol (Oxf)* 2015; 83: 420–428.
 64. Yerci O, Sehitoğlu I, Ugras N et al. Somatostatin receptor 2 and 5 expressions in gastroenteropancreatic neuroendocrine tumors in Turkey. *Asian Pac J Cancer Prev* 2015; 16: 4377–4381.
 65. Jones CD, Cummings IG, Shipolini AR, McCormack DJ. Does surgery improve prognosis in patients with small-cell lung carcinoma? *Interact Cardiovasc Thorac Surg* 2013; 16: 375–380.
 66. Joshi M, Ayoola A, Belani CP. Small-cell lung cancer: an update on targeted therapies. *Adv Exp Med Biol* 2013; 779: 385–404.
 67. Travis WD: Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. *Mod Pathol* 2012; 25 (Suppl 1): S18–30.
 68. Swarts DR, Ramaekers FC, Speel EJ. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. *Biochim Biophys Acta* 2012; 1826: 255–271.
 69. Travis WD. Advances in neuroendocrine lung tumors. *Ann Oncol* 2010; 21 (Suppl 7): vii65–71.
 70. Bertino EM, Confer PD, Colonna JE et al. Pulmonary neuroendocrine/carcinoid tumors: a review article. *Cancer* 2009; 115: 4434–4441.
 71. Tsuta K, Wistuba II, Moran CA. Differential expression of somatostatin receptors 1-5 in neuroendocrine carcinoma of the lung. *Pathol Res Pract* 2012; 208: 470–474.
 72. Kanakis G, Grimelius L, Spathis A et al. Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role. *Neuroendocrinology* 2015; 101: 211–222.
 73. Eisenhofer G, Tischler AS, de Krijger RR. Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification. *Endocr Pathol* 2012; 23: 4–14.
 74. Mete O, Tischler AS, De Krijger R et al. Protocol for the examination of specimens from patients with pheochromocytomas and extraadrenal paragangliomas. *Arch Pathol Lab Med* 2014; 138: 182–188.
 75. Pacak K, Eisenhofer G, Ahlman H et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. *Nat Clin Pract Endocrinol Metab* 2007; 3: 92–102.
 76. Tischler AS. Pheochromocytoma and extra-adrenal paraganglioma: updates. *Arch Pathol Lab Med* 2008; 132: 1272–1284.
 77. Saveanu A, Muresan M, De Micco C et al. Expression of somatostatin receptors, dopamine D₂ receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas. *Endocr Relat Cancer* 2011; 18: 287–300.
 78. Amber K, McLeod MP, Nouri K. The Merkel cell polyomavirus and its involvement in Merkel cell carcinoma. *Dermatol Surg* 2013; 39: 232–238.
 79. Daoud MA, Mete O, Al Habeeb A, Ghazarian D. Neuroendocrine carcinoma of the skin: an updated review. *Semin Diagn Pathol* 2013; 30: 234–244.
 80. Haneke E. Electron microscopy of Merkel cell carcinoma from formalin-fixed tissue. *J Am Acad Dermatol* 1985; 12: 487–492.
 81. Isimbaldi G, Sironi M, Taccagni GL et al. Tripartite differentiation (squamous, glandular, and melanocytic) of a primary cutaneous neuroendocrine carcinoma: an immunocytochemical and ultrastructural study. *Am J Dermatopathol* 1993; 15: 260–264.
 82. Ratner D, Nelson BR, Brown MD, Johnson TM. Merkel cell carcinoma. *J Am Acad Dermatol* 1993; 29: 143–156.
 83. Smith KJ, Skelton HG 3rd, Holland TT et al. Neuroendocrine (Merkel cell) carcinoma with an intraepidermal component. *Am J Dermatopathol* 1993; 15: 528–533.
 84. Gardair C, Samimi M, Touzé A et al. Somatostatin Receptors 2A and 5 Are Expressed in Merkel Cell Carcinoma with No Association with Disease Severity. *Neuroendocrinology* 2015; 101: 223–235.
 85. Adam A, Hochholzer L. Ganglioneuroblastoma of the posterior mediastinum: a clinicopathologic review of 80 cases. *Cancer* 1981; 47: 373–381.
 86. Ambros PF, Ambros IM, Strehl S et al. Regression and progression in neuroblastoma. Does genetics predict tumor behavior? *Eur J Cancer* 1995; 31A: 510–515.
 87. Brodeur GM. Molecular basis for heterogeneity in human neuroblastomas. *Eur J Cancer* 1995; 31A: 505–510.
 88. Devoe K, Weidner N. Immunohistochemistry of small round cell tumors. *Semin Diagn Pathol* 2000; 17: 216–224.
 89. Joshi VV. Peripheral neuroblastic tumors: Pathologic classification based on recommendations of international neuroblastoma pathology commit-

- tee (modification of Shimada classification). *Pediatr Dev Pathol* 2000; 3: 184–199.
90. Young DG. Thoracic neuroblastoma/ganglioneuroma. *J Pediatr Surg* 1983; 18: 37–41.
91. Watanabe N, Nakanishi Y, Kinukawa N et al. Expressions of Somatostatin Receptor Subtypes (SSTR-1, 2, 3, 4 and 5) in Neuroblastic Tumors; Special Reference to Clinicopathological Correlations with International Neuroblastoma Pathology Classification and Outcomes. *Acta Histochem Cytochem* 2014; 47: 219–229.
92. Guyetant S, Josselin N, Savagner F et al. C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients. *Mod Pathol* 2003; 16: 756–763.
93. Leboulleux S, Baudin E, Travagli JP, Schlumberger M: Medullary thyroid carcinoma. *Clin Endocrinol (Oxf)* 2004; 61: 299–310.
94. Massoll N, Mazzaferri EL. Diagnosis and management of medullary thyroid carcinoma. *Clin Lab Med* 2004; 24: 49–83.
95. Simpson NE, Kidd KK, Goodfellow PJ et al. Assignment of multiple endocrine neoplasia type IIA to chromosome 10 by linkage. *Nature* 1987; 328: 528–530.
96. Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. *Clin Endocrinol (Oxf)* 2001; 54: 641–649.
97. Woelfl S, Bogner S, Huber H et al. Expression of somatostatin receptor subtype 2 and subtype 5 in thyroid malignancies. *Nuklearmedizin* 2014; 53: 179–185.
98. Pisarek H, Stepień T, Kubiak R, Borkowska E, Pawlikowski M. Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation. *Thyroid Res* 2009; 2: 1.
99. Mizutani G, Nakanishi Y, Watanabe N et al. Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry. *Acta Histochem Cytochem* 2012; 45: 167–176.